About
Cancer therapies
Areas of Focus
Categories
Small Molecule PharmaceuticalSoutheastern U.S.
Clinical Trials (13)
View allTotal Trials
13
As Lead Sponsor
7
As Collaborator
6
Total Enrollment
960
By Phase
EARLY_PHASE1: 1PHASE1/PHASE2: 3PHASE2: 3PHASE1: 3PHASE4: 1PHASE3: 2
By Status
COMPLETED: 5TERMINATED: 3RECRUITING: 2ACTIVE_NOT_RECRUITING: 2NOT_YET_RECRUITING: 1
Clinical Trials Pipeline13 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT06831526Collaborator
Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
EARLY_PHASE1Not yet recruiting
12 participants
Started: Oct 31, 2025 · Completed: Jul 31, 2030
NCT05789589Collaborator
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
PHASE1/PHASE2Recruiting
46 participants
Started: Nov 17, 2023 · Completed: Aug 31, 2027
NCT05986851Lead Sponsor
Azeliragon in MGMT Unmethylated Glioblastoma
PHASE2Active, not recruiting
30 participants
Started: Sep 12, 2023 · Completed: Jun 30, 2025
NCT05635734Lead Sponsor
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
PHASE1/PHASE2Active, not recruiting
18 participants
Started: Sep 5, 2023 · Completed: Dec 31, 2025
NCT05766748Lead Sponsor
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
PHASE1/PHASE2Recruiting
30 participants
Started: Jun 1, 2023 · Completed: May 31, 2025
Locations (1)
Headquarters
Weston, FL, United States
Map
Loading map...